Skin Diseases Treatment Market Size by Product Type, Type of Diseases, End-Users, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2030
3.67%
CAGR (2024-2030)
3.8 USD Bn.
Market Size
304
Report Pages
162
Market Tables
Overview
The Skin Diseases Treatment Market value is projected to reach US$ 4.89 Bn 2030 at the end of the forecast period and it is expected to grow at the CAGR of 3.67%.
Skin Diseases Treatment Market Overview:
Skin Diseases Treatment or Dermatology is a fast-paced industry over the past decade owing to the rising prevalence of skin diseases. Various innovative therapies are being developed to combat skin diseases.
Various factors are contributing to the growth of the Skin Disease Treatment market, which includes demand for topical dermatological drugs. Also, rising awareness about various skin diseases coupled with rapid diagnosis techniques, surge in skin cancer prominently drive the market upwards. However, lack of awareness about drugs used in the treatment of skin diseases and stringent government regulations may restrain the market growth.
Development of innovative products and increase in the number of mergers and acquisitions by key vendors are expected to provide numerous opportunities for this market. Artificial or bioengineered skin substitutes have made revolutionary developments in skin disease treatment.
To know about the Research Methodology :- Request Free Sample Report
Skin Diseases Treatment Market Regional Analysis:
North America holds the most prominent market share for skin disease treatment and is expected to dominate throughout the forecast period. Following this trend, Europe is also expected to dominate the global skin disease treatment market in the upcoming years. Technological advances and the availability of the latest products and devices for skin disease treatment are the key factors that drive the demand of the market in these regions.
APAC is also expected to witness strong growth in upcoming years due to increasing awareness, massive population base and ongoing technological advancements. Growing medical tourism in countries like Thailand, India, Singapore, South Korea, and Malaysia has spurred the demand for skin disease treatment from countries around the world.
Skin Diseases Treatment Market Segment analysis:
Autoimmune skin diseases segment grows remarkably owing to the development of new therapies, dermatological drugs are expected to add revenue in the autoimmune skin diseases treatment market. Autoimmune skin diseases treatment consists of drug a class act on autoimmune skin diseases which are a heterogeneous group of conditions clinically characterized by blisters and erosions on the skin and close-to-surface mucous membranes.
The objective of the report is to present a comprehensive analysis of the Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Market dynamics, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.
Skin Diseases Treatment Market Scope: Inquire before buying
| Skin Diseases Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | US $ 3.80 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 3.67% | Market Size in 2030: | US $ 4.89 Bn. |
| Segments Covered: | by Product Type | Medicated creams and Ointments Antibiotics and Vitamins Steroids Laser Therapy Antifungals |
|
| by Type of Diseases | Autoimmune skin diseases Genetic skin diseases Allergic skin diseases Infectious Skin diseases Skin cancers |
||
| by End-Users | Dermatology clinics Skincare clinics Hospitals Aesthetic centres |
||
Skin Diseases Treatment Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Key players operating in the skin Diseases Treatment market:
1. Pfizer Inc.
2. Allergen Plc.
3. Celgene Corporation
4. Abbvie Inc.
5. Eli Lilly and Company
6. GlaxoSmithKline Plc.
7. Galderma
8. Incyte corporation
9. Valeant Pharmaceuticals International Inc.
10. Almirall S.A.
11. Bayer AG
12. Johnson & Johnson
13. Novartis AG
14. AstraZeneca
15. Amgen Inc.
16. Merck KGaA
17. Cipher pharmaceuticals
Frequently Asked Questions:
1. Which region has the largest share in Global Market?
Ans: North America region held the highest share in 2023.
2. What is the growth rate of Global Skin Diseases Treatment Market?
Ans: The Global Skin Diseases Treatment Market is growing at a CAGR of 3.67% during forecasting period 2024-2030.
3. What is scope of the Global Skin Diseases Treatment Market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – Pfizer Inc., Allergen Plc., Celgene Corporation, Abbvie Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Galderma, Incyte corporation, Valeant Pharmaceuticals International Inc., Almirall S.A., Bayer AG, Johnson & Johnson, Novartis AG, AstraZeneca, Amgen Inc., Merck KGaA, Cipher pharmaceuticals, Janssen biotech, Kaken Pharmaceuticals, and Regeneron pharmaceuticals Inc.
5. What is the study period of this Market?
Ans: The Global Market is studied from 2023 to 2030.
Table of Contents
Global Skin Diseases Treatment Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Skin Diseases Treatment Size, By Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Skin Diseases Treatment Analysis and Forecast
6.1. Skin Diseases Treatment Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Skin Diseases Treatment Analysis and Forecast, By Product Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Skin Diseases Treatment Value Share Analysis, By Product Type
7.4. Skin Diseases Treatment Size (US$ Mn) Forecast, By Product Type
7.5. Skin Diseases Treatment Analysis, By Product Type
7.6. Skin Diseases Treatment Attractiveness Analysis, By Product Type
8. Global Skin Diseases Treatment Analysis and Forecast, By Type of Diseases
8.1. Introduction and Definition
8.2. Key Findings
8.3. Skin Diseases Treatment Value Share Analysis, By Type of Diseases
8.4. Skin Diseases Treatment Size (US$ Mn) Forecast, By Type of Diseases
8.5. Skin Diseases Treatment Analysis, By Type of Diseases
8.6. Skin Diseases Treatment Attractiveness Analysis, By Type of Diseases
9. Global Skin Diseases Treatment Analysis and Forecast By End-Users
9.1. Introduction and Definition
9.2. Key Findings
9.3. Skin Diseases Treatment Value Share Analysis, By End-Users
9.4. Skin Diseases Treatment Size (US$ Mn) Forecast, By End-Users
9.5. Skin Diseases Treatment Analysis, By End-Users
9.6. Skin Diseases Treatment Attractiveness Analysis, By End-Users
10. Global Skin Diseases Treatment Analysis, By Region
10.1. Skin Diseases Treatment Value Share Analysis, By Region
10.2. Skin Diseases Treatment Size (US$ Mn) Forecast, By Region
10.3. Skin Diseases Treatment Attractiveness Analysis, By Region
11. North America Skin Diseases Treatment Analysis
11.1. Key Findings
11.2. North America Skin Diseases Treatment Overview
11.3. North America Skin Diseases Treatment Value Share Analysis, By Product Type
11.4. North America Skin Diseases Treatment Forecast, By Product Type
11.4.1. Medicated creams and Ointments
11.4.2. Antibiotics and Vitamins
11.4.3. Steroids
11.4.4. Laser Therapy
11.4.5. Antifungals
11.5. North America Skin Diseases Treatment Value Share Analysis, By Type of Diseases
11.6. North America Skin Diseases Treatment Forecast, By Type of Diseases
11.6.1. Autoimmune skin diseases
11.6.2. Genetic skin diseases
11.6.3. Allergic skin diseases
11.6.4. Infectious Skin diseases
11.6.5. Skin cancers
11.7. North America Skin Diseases Treatment Value Share Analysis, By End-Users
11.8. North America Skin Diseases Treatment Forecast, By End-Users
11.8.1. Dermatology clinics
11.8.2. Skincare clinics
11.8.3. Hospitals
11.8.4. Aesthetic centres
11.9. North America Skin Diseases Treatment Value Share Analysis, By Country
11.10. North America Skin Diseases Treatment Forecast, By Country
11.10.1. U.S.
11.10.2. Canada
11.10.3. Mexico
11.11. North America Skin Diseases Treatment Analysis, By Country
11.12. U.S. Skin Diseases Treatment Forecast, By Product Type
11.12.1. Medicated creams and Ointments
11.12.2. Antibiotics and Vitamins
11.12.3. Steroids
11.12.4. Laser Therapy
11.12.5. Antifungals
11.13. U.S. Skin Diseases Treatment Forecast, By Type of Diseases
11.13.1. Autoimmune skin diseases
11.13.2. Genetic skin diseases
11.13.3. Allergic skin diseases
11.13.4. Infectious Skin diseases
11.13.5. Skin cancers
11.14. U.S. Skin Diseases Treatment Forecast, By End-Users
11.14.1. Dermatology clinics
11.14.2. Skincare clinics
11.14.3. Hospitals
11.14.4. Aesthetic centres
11.15. Canada Skin Diseases Treatment Forecast, By Product Type
11.15.1. Medicated creams and Ointments
11.15.2. Antibiotics and Vitamins
11.15.3. Steroids
11.15.4. Laser Therapy
11.15.5. Antifungals
11.16. Canada Skin Diseases Treatment Forecast, By Type of Diseases
11.16.1. Autoimmune skin diseases
11.16.2. Genetic skin diseases
11.16.3. Allergic skin diseases
11.16.4. Infectious Skin diseases
11.16.5. Skin cancers
11.17. Canada Skin Diseases Treatment Forecast, By End-Users
11.17.1. Dermatology clinics
11.17.2. Skincare clinics
11.17.3. Hospitals
11.17.4. Aesthetic centres
11.18. Mexico Skin Diseases Treatment Forecast, By Product Type
11.18.1. Medicated creams and Ointments
11.18.2. Antibiotics and Vitamins
11.18.3. Steroids
11.18.4. Laser Therapy
11.18.5. Antifungals
11.19. Mexico Skin Diseases Treatment Forecast, By Type of Diseases
11.19.1. Autoimmune skin diseases
11.19.2. Genetic skin diseases
11.19.3. Allergic skin diseases
11.19.4. Infectious Skin diseases
11.19.5. Skin cancers
11.20. Mexico Skin Diseases Treatment Forecast, By End-Users
11.20.1. Dermatology clinics
11.20.2. Skincare clinics
11.20.3. Hospitals
11.20.4. Aesthetic centres
11.21. North America Skin Diseases Treatment Attractiveness Analysis
11.21.1. By Product Type
11.21.2. By Type of Diseases
11.21.3. By End-Users
11.22. PEST Analysis
11.23. Key Trends
11.24. Key Developments
12. Europe Skin Diseases Treatment Analysis
12.1. Key Findings
12.2. Europe Skin Diseases Treatment Overview
12.3. Europe Skin Diseases Treatment Value Share Analysis, By Product Type
12.4. Europe Skin Diseases Treatment Forecast, By Product Type
12.4.1. Medicated creams and Ointments
12.4.2. Antibiotics and Vitamins
12.4.3. Steroids
12.4.4. Laser Therapy
12.4.5. Antifungals
12.5. Europe Skin Diseases Treatment Value Share Analysis, By Type of Diseases
12.6. Europe Skin Diseases Treatment Forecast, By Type of Diseases
12.6.1. Autoimmune skin diseases
12.6.2. Genetic skin diseases
12.6.3. Allergic skin diseases
12.6.4. Infectious Skin diseases
12.6.5. Skin cancers
12.7. Europe Skin Diseases Treatment Value Share Analysis, By End-Users
12.8. Europe Skin Diseases Treatment Forecast, By End-Users
12.8.1. Dermatology clinics
12.8.2. Skincare clinics
12.8.3. Hospitals
12.8.4. Aesthetic centres
12.9. Europe Skin Diseases Treatment Value Share Analysis, By Country
12.10. Europe Skin Diseases Treatment Forecast, By Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Sweden
12.10.7. CIS countries
12.10.8. Rest of Europe
12.11. Germany Skin Diseases Treatment Forecast, By Product Type
12.11.1. Medicated creams and Ointments
12.11.2. Antibiotics and Vitamins
12.11.3. Steroids
12.11.4. Laser Therapy
12.11.5. Antifungals
12.12. Germany Skin Diseases Treatment Forecast, By Type of Diseases
12.12.1. Autoimmune skin diseases
12.12.2. Genetic skin diseases
12.12.3. Allergic skin diseases
12.12.4. Infectious Skin diseases
12.12.5. Skin cancers
12.13. Germany Skin Diseases Treatment Forecast, By End-Users
12.13.1. Dermatology clinics
12.13.2. Skincare clinics
12.13.3. Hospitals
12.13.4. Aesthetic centres
12.14. U.K. Skin Diseases Treatment Forecast, By Product Type
12.14.1. Medicated creams and Ointments
12.14.2. Antibiotics and Vitamins
12.14.3. Steroids
12.14.4. Laser Therapy
12.14.5. Antifungals
12.15. U.K. Skin Diseases Treatment Forecast, By Type of Diseases
12.15.1. Autoimmune skin diseases
12.15.2. Genetic skin diseases
12.15.3. Allergic skin diseases
12.15.4. Infectious Skin diseases
12.15.5. Skin cancers
12.16. U.K. Skin Diseases Treatment Forecast, By End-Users
12.16.1. Dermatology clinics
12.16.2. Skincare clinics
12.16.3. Hospitals
12.16.4. Aesthetic centres
12.17. France Skin Diseases Treatment Forecast, By Product Type
12.17.1. Medicated creams and Ointments
12.17.2. Antibiotics and Vitamins
12.17.3. Steroids
12.17.4. Laser Therapy
12.17.5. Antifungals
12.18. France Skin Diseases Treatment Forecast, By Type of Diseases
12.18.1. Autoimmune skin diseases
12.18.2. Genetic skin diseases
12.18.3. Allergic skin diseases
12.18.4. Infectious Skin diseases
12.18.5. Skin cancers
12.19. France Skin Diseases Treatment Forecast, By End-Users
12.19.1. Dermatology clinics
12.19.2. Skincare clinics
12.19.3. Hospitals
12.19.4. Aesthetic centres
12.20. Italy Skin Diseases Treatment Forecast, By Product Type
12.20.1. Medicated creams and Ointments
12.20.2. Antibiotics and Vitamins
12.20.3. Steroids
12.20.4. Laser Therapy
12.20.5. Antifungals
12.21. Italy Skin Diseases Treatment Forecast, By Type of Diseases
12.21.1. Autoimmune skin diseases
12.21.2. Genetic skin diseases
12.21.3. Allergic skin diseases
12.21.4. Infectious Skin diseases
12.21.5. Skin cancers
12.22. Italy Skin Diseases Treatment Forecast, By End-Users
12.22.1. Dermatology clinics
12.22.2. Skincare clinics
12.22.3. Hospitals
12.22.4. Aesthetic centres
12.23. Spain Skin Diseases Treatment Forecast, By Product Type
12.23.1. Medicated creams and Ointments
12.23.2. Antibiotics and Vitamins
12.23.3. Steroids
12.23.4. Laser Therapy
12.23.5. Antifungals
12.24. Spain Skin Diseases Treatment Forecast, By Type of Diseases
12.24.1. Autoimmune skin diseases
12.24.2. Genetic skin diseases
12.24.3. Allergic skin diseases
12.24.4. Infectious Skin diseases
12.24.5. Skin cancers
12.25. Spain Skin Diseases Treatment Forecast, By End-Users
12.25.1. Dermatology clinics
12.25.2. Skincare clinics
12.25.3. Hospitals
12.25.4. Aesthetic centres
12.26. Sweden Skin Diseases Treatment Forecast, By Product Type
12.26.1. Medicated creams and Ointments
12.26.2. Antibiotics and Vitamins
12.26.3. Steroids
12.26.4. Laser Therapy
12.26.5. Antifungals
12.27. Sweden Skin Diseases Treatment Forecast, By Type of Diseases
12.27.1. Autoimmune skin diseases
12.27.2. Genetic skin diseases
12.27.3. Allergic skin diseases
12.27.4. Infectious Skin diseases
12.27.5. Skin cancers
12.28. Sweden Skin Diseases Treatment Forecast, By End-Users
12.28.1. Dermatology clinics
12.28.2. Skincare clinics
12.28.3. Hospitals
12.28.4. Aesthetic centres
12.29. CIS countries Skin Diseases Treatment Forecast, By Product Type
12.29.1. Medicated creams and Ointments
12.29.2. Antibiotics and Vitamins
12.29.3. Steroids
12.29.4. Laser Therapy
12.29.5. Antifungals
12.30. CIS countries Skin Diseases Treatment Forecast, By Type of Diseases
12.30.1. Autoimmune skin diseases
12.30.2. Genetic skin diseases
12.30.3. Allergic skin diseases
12.30.4. Infectious Skin diseases
12.30.5. Skin cancers
12.31. CIS countries Skin Diseases Treatment Forecast, By End-Users
12.31.1. Dermatology clinics
12.31.2. Skincare clinics
12.31.3. Hospitals
12.31.4. Aesthetic centres
12.32. Rest of Europe Skin Diseases Treatment Forecast, By Product Type
12.32.1. Medicated creams and Ointments
12.32.2. Antibiotics and Vitamins
12.32.3. Steroids
12.32.4. Laser Therapy
12.32.5. Antifungals
12.33. Rest of Europe Skin Diseases Treatment Forecast, By Type of Diseases
12.33.1. Autoimmune skin diseases
12.33.2. Genetic skin diseases
12.33.3. Allergic skin diseases
12.33.4. Infectious Skin diseases
12.33.5. Skin cancers
12.34. Rest of Europe Skin Diseases Treatment Forecast, By End-Users
12.34.1. Dermatology clinics
12.34.2. Skincare clinics
12.34.3. Hospitals
12.34.4. Aesthetic centres
12.35. Europe Skin Diseases Treatment Attractiveness Analysis
12.35.1. By Type of Diseases
12.35.2. By Product Type
12.35.3. By End-Users
12.36. PEST Analysis
12.37. Key Trends
12.38. Key Developments
13. Asia Pacific Skin Diseases Treatment Analysis
13.1. Key Findings
13.2. Asia Pacific Skin Diseases Treatment Overview
13.3. Asia Pacific Skin Diseases Treatment Value Share Analysis, By Product Type
13.4. Asia Pacific Skin Diseases Treatment Forecast, By Product Type
13.4.1. Medicated creams and Ointments
13.4.2. Antibiotics and Vitamins
13.4.3. Steroids
13.4.4. Laser Therapy
13.4.5. Antifungals
13.5. Asia Pacific Skin Diseases Treatment Value Share Analysis, By Type of Diseases
13.6. Asia Pacific Skin Diseases Treatment Forecast, By Type of Diseases
13.6.1. Autoimmune skin diseases
13.6.2. Genetic skin diseases
13.6.3. Allergic skin diseases
13.6.4. Infectious Skin diseases
13.6.5. Skin cancers
13.7. Asia Pacific Skin Diseases Treatment Value Share Analysis, By End-Users
13.8. Asia Pacific Skin Diseases Treatment Forecast, By End-Users
13.8.1. Dermatology clinics
13.8.2. Skincare clinics
13.8.3. Hospitals
13.8.4. Aesthetic centres
13.9. Asia Pacific Skin Diseases Treatment Value Share Analysis, By Country
13.10. Asia Pacific Skin Diseases Treatment Forecast, By Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. South Korea
13.10.5. Australia
13.10.6. ASEAN
13.10.7. Rest of Asia Pacific
13.11. Asia Pacific Skin Diseases Treatment Analysis, By Country
13.12. China Skin Diseases Treatment Forecast, By Product Type
13.12.1. Medicated creams and Ointments
13.12.2. Antibiotics and Vitamins
13.12.3. Steroids
13.12.4. Laser Therapy
13.12.5. Antifungals
13.13. China Skin Diseases Treatment Forecast, By Type of Diseases
13.13.1. Autoimmune skin diseases
13.13.2. Genetic skin diseases
13.13.3. Allergic skin diseases
13.13.4. Infectious Skin diseases
13.13.5. Skin cancers
13.14. China Skin Diseases Treatment Forecast, By End-Users
13.14.1. Dermatology clinics
13.14.2. Skincare clinics
13.14.3. Hospitals
13.14.4. Aesthetic centres
13.15. India Skin Diseases Treatment Forecast, By Product Type
13.15.1. Medicated creams and Ointments
13.15.2. Antibiotics and Vitamins
13.15.3. Steroids
13.15.4. Laser Therapy
13.15.5. Antifungals
13.16. India Skin Diseases Treatment Forecast, By Type of Diseases
13.16.1. Autoimmune skin diseases
13.16.2. Genetic skin diseases
13.16.3. Allergic skin diseases
13.16.4. Infectious Skin diseases
13.16.5. Skin cancers
13.17. India Skin Diseases Treatment Forecast, By End-Users
13.17.1. Dermatology clinics
13.17.2. Skincare clinics
13.17.3. Hospitals
13.17.4. Aesthetic centres
13.18. Japan Skin Diseases Treatment Forecast, By Product Type
13.18.1. Medicated creams and Ointments
13.18.2. Antibiotics and Vitamins
13.18.3. Steroids
13.18.4. Laser Therapy
13.18.5. Antifungals
13.19. Japan Skin Diseases Treatment Forecast, By Type of Diseases
13.19.1. Autoimmune skin diseases
13.19.2. Genetic skin diseases
13.19.3. Allergic skin diseases
13.19.4. Infectious Skin diseases
13.19.5. Skin cancers
13.20. Japan Skin Diseases Treatment Forecast, By End-Users
13.20.1. Dermatology clinics
13.20.2. Skincare clinics
13.20.3. Hospitals
13.20.4. Aesthetic centres
13.21. South Korea Skin Diseases Treatment Forecast, By Product Type
13.21.1. Medicated creams and Ointments
13.21.2. Antibiotics and Vitamins
13.21.3. Steroids
13.21.4. Laser Therapy
13.21.5. Antifungals
13.22. South Korea Skin Diseases Treatment Forecast, By Type of Diseases
13.22.1. Autoimmune skin diseases
13.22.2. Genetic skin diseases
13.22.3. Allergic skin diseases
13.22.4. Infectious Skin diseases
13.22.5. Skin cancers
13.23. South Korea Skin Diseases Treatment Forecast, By End-Users
13.23.1. Dermatology clinics
13.23.2. Skincare clinics
13.23.3. Hospitals
13.23.4. Aesthetic centres
13.24. Australia Skin Diseases Treatment Forecast, By Product Type
13.24.1. Medicated creams and Ointments
13.24.2. Antibiotics and Vitamins
13.24.3. Steroids
13.24.4. Laser Therapy
13.24.5. Antifungals
13.25. Australia Skin Diseases Treatment Forecast, By Type of Diseases
13.25.1. Autoimmune skin diseases
13.25.2. Genetic skin diseases
13.25.3. Allergic skin diseases
13.25.4. Infectious Skin diseases
13.25.5. Skin cancers
13.26. Australia Skin Diseases Treatment Forecast, By End-Users
13.26.1. Dermatology clinics
13.26.2. Skincare clinics
13.26.3. Hospitals
13.26.4. Aesthetic centres
13.27. ASEAN Skin Diseases Treatment Forecast, By Product Type
13.27.1. Medicated creams and Ointments
13.27.2. Antibiotics and Vitamins
13.27.3. Steroids
13.27.4. Laser Therapy
13.27.5. Antifungals
13.28. ASEAN Skin Diseases Treatment Forecast, By Type of Diseases
13.28.1. Autoimmune skin diseases
13.28.2. Genetic skin diseases
13.28.3. Allergic skin diseases
13.28.4. Infectious Skin diseases
13.28.5. Skin cancers
13.29. ASEAN Skin Diseases Treatment Forecast, By End-Users
13.29.1. Dermatology clinics
13.29.2. Skincare clinics
13.29.3. Hospitals
13.29.4. Aesthetic centres
13.30. Rest of Asia Pacific Skin Diseases Treatment Forecast, By Product Type
13.30.1. Medicated creams and Ointments
13.30.2. Antibiotics and Vitamins
13.30.3. Steroids
13.30.4. Laser Therapy
13.30.5. Antifungals
13.31. Rest of Asia Pacific Skin Diseases Treatment Forecast, By Type of Diseases
13.31.1. Autoimmune skin diseases
13.31.2. Genetic skin diseases
13.31.3. Allergic skin diseases
13.31.4. Infectious Skin diseases
13.31.5. Skin cancers
13.32. Rest of Asia Pacific Skin Diseases Treatment Forecast, By End-Users
13.32.1. Dermatology clinics
13.32.2. Skincare clinics
13.32.3. Hospitals
13.32.4. Aesthetic centres
13.33. Asia Pacific Skin Diseases Treatment Attractiveness Analysis
13.33.1. By Product Type
13.33.2. By Type of Diseases
13.33.3. By End-Users
13.34. PEST Analysis
13.35. Key Trends
13.36. Key Developments
14. Middle East & Africa Skin Diseases Treatment Analysis
14.1. Key Findings
14.2. Middle East & Africa Skin Diseases Treatment Overview
14.3. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By Product Type
14.4. Middle East & Africa Skin Diseases Treatment Forecast, By Product Type
14.4.1. Medicated creams and Ointments
14.4.2. Antibiotics and Vitamins
14.4.3. Steroids
14.4.4. Laser Therapy
14.4.5. Antifungals
14.5. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By Type of Diseases
14.6. Middle East & Africa Skin Diseases Treatment Forecast, By Type of Diseases
14.6.1. Autoimmune skin diseases
14.6.2. Genetic skin diseases
14.6.3. Allergic skin diseases
14.6.4. Infectious Skin diseases
14.6.5. Skin cancers
14.7. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By End-Users
14.8. Middle East & Africa Skin Diseases Treatment Forecast, By End-Users
14.8.1. Dermatology clinics
14.8.2. Skincare clinics
14.8.3. Hospitals
14.8.4. Aesthetic centres
14.9. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By Country
14.10. Middle East & Africa Skin Diseases Treatment Forecast, By Country
14.10.1. GCC Countries
14.10.2. South Africa
14.10.3. Nigeria
14.10.4. Egypt
14.10.5. Rest of Middle East & Africa
14.11. Middle East & Africa Skin Diseases Treatment Analysis, By Country
14.12. GCC Countries Skin Diseases Treatment Forecast, By Product Type
14.12.1. Medicated creams and Ointments
14.12.2. Antibiotics and Vitamins
14.12.3. Steroids
14.12.4. Laser Therapy
14.12.5. Antifungals
14.13. GCC Countries Skin Diseases Treatment Forecast, By Type of Diseases
14.13.1. Autoimmune skin diseases
14.13.2. Genetic skin diseases
14.13.3. Allergic skin diseases
14.13.4. Infectious Skin diseases
14.13.5. Skin cancers
14.14. GCC Countries Skin Diseases Treatment Forecast, By End-Users
14.14.1. Dermatology clinics
14.14.2. Skincare clinics
14.14.3. Hospitals
14.14.4. Aesthetic centres
14.15. South Africa Skin Diseases Treatment Forecast, By Product Type
14.15.1. Medicated creams and Ointments
14.15.2. Antibiotics and Vitamins
14.15.3. Steroids
14.15.4. Laser Therapy
14.15.5. Antifungals
14.16. South Africa Skin Diseases Treatment Forecast, By Type of Diseases
14.16.1. Autoimmune skin diseases
14.16.2. Genetic skin diseases
14.16.3. Allergic skin diseases
14.16.4. Infectious Skin diseases
14.16.5. Skin cancers t
14.17. South Africa Skin Diseases Treatment Forecast, By End-Users
14.17.1. Dermatology clinics
14.17.2. Skincare clinics
14.17.3. Hospitals
14.17.4. Aesthetic centres
14.18. Nigeria Skin Diseases Treatment Forecast, By Product Type
14.18.1. Medicated creams and Ointments
14.18.2. Antibiotics and Vitamins
14.18.3. Steroids
14.18.4. Laser Therapy
14.18.5. Antifungals
14.19. Nigeria Skin Diseases Treatment Forecast, By Type of Diseases
14.19.1. Autoimmune skin diseases
14.19.2. Genetic skin diseases
14.19.3. Allergic skin diseases
14.19.4. Infectious Skin diseases
14.19.5. Skin cancers
14.20. Nigeria Skin Diseases Treatment Forecast, By End-Users
14.20.1. Dermatology clinics
14.20.2. Skincare clinics
14.20.3. Hospitals
14.20.4. Aesthetic centres
14.21. Egypt Skin Diseases Treatment Forecast, By Product Type
14.21.1. Medicated creams and Ointments
14.21.2. Antibiotics and Vitamins
14.21.3. Steroids
14.21.4. Laser Therapy
14.21.5. Antifungals
14.22. Egypt Skin Diseases Treatment Forecast, By Type of Diseases
14.22.1. Autoimmune skin diseases
14.22.2. Genetic skin diseases
14.22.3. Allergic skin diseases
14.22.4. Infectious Skin diseases
14.22.5. Skin cancers
14.23. Egypt Skin Diseases Treatment Forecast, By End-Users
14.23.1. Dermatology clinics
14.23.2. Skincare clinics
14.23.3. Hospitals
14.23.4. Aesthetic centres
14.24. Rest of Middle East & Africa Skin Diseases Treatment Forecast, By Product Type
14.24.1. Medicated creams and Ointments
14.24.2. Antibiotics and Vitamins
14.24.3. Steroids
14.24.4. Laser Therapy
14.24.5. Antifungals
14.25. Rest of Middle East & Africa Skin Diseases Treatment Forecast, By Type of Diseases
14.25.1. Autoimmune skin diseases
14.25.2. Genetic skin diseases
14.25.3. Allergic skin diseases
14.25.4. Infectious Skin diseases
14.25.5. Skin cancers
14.26. Rest of Middle East & Africa Skin Diseases Treatment Forecast, By End-Users
14.26.1. Dermatology clinics
14.26.2. Skincare clinics
14.26.3. Hospitals
14.26.4. Aesthetic centres
14.27. Middle East & Africa Skin Diseases Treatment Attractiveness Analysis
14.27.1. By Product Type
14.27.2. By Type of Diseases
14.27.3. By End-Users
14.28. PEST Analysis
14.29. Key Trends
14.30. Key Developments
15. South America Skin Diseases Treatment Analysis
15.1. Key Findings
15.2. South America Skin Diseases Treatment Overview
15.3. South America Skin Diseases Treatment Value Share Analysis, By Product Type
15.4. South America Skin Diseases Treatment Forecast, By Product Type
15.4.1. Medicated creams and Ointments
15.4.2. Antibiotics and Vitamins
15.4.3. Steroids
15.4.4. Laser Therapy
15.4.5. Antifungals
15.5. South America Skin Diseases Treatment Value Share Analysis, By Type of Diseases
15.6. South America Skin Diseases Treatment Forecast, By Type of Diseases
15.6.1. Autoimmune skin diseases
15.6.2. Genetic skin diseases
15.6.3. Allergic skin diseases
15.6.4. Infectious Skin diseases
15.6.5. Skin cancers
15.7. South America Skin Diseases Treatment Value Share Analysis, By End-Users
15.8. South America Skin Diseases Treatment Forecast, By End-Users
15.8.1. Dermatology clinics
15.8.2. Skincare clinics
15.8.3. Hospitals
15.8.4. Aesthetic centres
15.9. South America Skin Diseases Treatment Value Share Analysis, By Country
15.10. South America Skin Diseases Treatment Forecast, By Country
15.10.1. Brazil
15.10.2. Colombia
15.10.3. Argentina
15.10.4. Rest of South America
15.11. South America Skin Diseases Treatment Analysis, By Country
15.12. Brazil Skin Diseases Treatment Forecast, By Product Type
15.12.1. Medicated creams and Ointments
15.12.2. Antibiotics and Vitamins
15.12.3. Steroids
15.12.4. Laser Therapy
15.12.5. Antifungals
15.13. Brazil Skin Diseases Treatment Forecast, By Type of Diseases
15.13.1. Autoimmune skin diseases
15.13.2. Genetic skin diseases
15.13.3. Allergic skin diseases
15.13.4. Infectious Skin diseases
15.13.5. Skin cancers
15.14. Brazil Skin Diseases Treatment Forecast, By End-Users
15.14.1. Dermatology clinics
15.14.2. Skincare clinics
15.14.3. Hospitals
15.14.4. Aesthetic centres
15.15. Colombia Skin Diseases Treatment Forecast, By Product Type
15.15.1. Medicated creams and Ointments
15.15.2. Antibiotics and Vitamins
15.15.3. Steroids
15.15.4. Laser Therapy
15.15.5. Antifungals
15.16. Colombia Skin Diseases Treatment Forecast, By Type of Diseases
15.16.1. Autoimmune skin diseases
15.16.2. Genetic skin diseases
15.16.3. Allergic skin diseases
15.16.4. Infectious Skin diseases
15.16.5. Skin cancers
15.17. Colombia Skin Diseases Treatment Forecast, By End-Users
15.17.1. Dermatology clinics
15.17.2. Skincare clinics
15.17.3. Hospitals
15.17.4. Aesthetic centres
15.18. Argentina Skin Diseases Treatment Forecast, By Product Type
15.18.1. Medicated creams and Ointments
15.18.2. Antibiotics and Vitamins
15.18.3. Steroids
15.18.4. Laser Therapy
15.18.5. Antifungals
15.19. Argentina Skin Diseases Treatment Forecast, By Type of Diseases
15.19.1. Autoimmune skin diseases
15.19.2. Genetic skin diseases
15.19.3. Allergic skin diseases
15.19.4. Infectious Skin diseases
15.19.5. Skin cancers
15.20. Argentina Skin Diseases Treatment Forecast, By End-Users
15.20.1. Dermatology clinics
15.20.2. Skincare clinics
15.20.3. Hospitals
15.20.4. Aesthetic centres
15.21. Rest of South America Skin Diseases Treatment Forecast, By Product Type
15.21.1. Medicated creams and Ointments
15.21.2. Antibiotics and Vitamins
15.21.3. Steroids
15.21.4. Laser Therapy
15.21.5. Antifungals
15.22. Rest of South America Skin Diseases Treatment Forecast, By Type of Diseases
15.22.1. Autoimmune skin diseases
15.22.2. Genetic skin diseases
15.22.3. Allergic skin diseases
15.22.4. Infectious Skin diseases
15.22.5. Skin cancers
15.23. Rest of South America Skin Diseases Treatment Forecast, By End-Users
15.23.1. Dermatology clinics
15.23.2. Skincare clinics
15.23.3. Hospitals
15.23.4. Aesthetic centres
15.24. South America Skin Diseases Treatment Attractiveness Analysis
15.24.1. By Product Type
15.24.2. By Type of Diseases
15.24.3. By End-Users
15.25. PEST Analysis
15.26. Key Trends
15.27. Key Developments
16. Company Profiles
16.1. Market Share Analysis, By Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A By Regions, Investment and Component
16.2.3.2. M&A Key Players, Forward Integration and Backward Integration
16.3. Company Profiles: Key Players
16.3.1. Pfizer Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Allergen Plc.
16.3.3. Celgene Corporation
16.3.4. Abbvie Inc.
16.3.5. Eli Lilly and Company
16.3.6. GlaxoSmithKline Plc.
16.3.7. Galderma
16.3.8. Incyte corporation
16.3.9. Valeant Pharmaceuticals International Inc.
16.3.10. Almirall S.A.
16.3.11. Bayer AG
16.3.12. Johnson & Johnson
16.3.13. Novartis AG
16.3.14. AstraZeneca
16.3.15. Amgen Inc.
16.3.16. Merck KGaA
16.3.17. Cipher pharmaceuticals
16.3.18. Janssen biotech
16.3.19. Kaken Pharmaceuticals
16.3.20. Regeneron pharmaceuticals Inc.